Having atopic comorbidities does not impact patch efficacy in peanut-allergic children

After 12 months of treatment, more 4- to 7-year-olds with peanut allergy using the Viaskin Peanut patch vs. placebo were deemed treatment responders regardless of atopic comorbidity status, according to phase 3 subgroup analysis findings.These data on the Viaskin Peanut patch (VP250, DBV Technologies) were presented at the 2026 European Academy of Allergy and Clinical Immunology Annual Congress.